AI Article Synopsis
- More than 50% of patients using CTLA-4 and PD-1 inhibitors experience skin side-effects, which dermatologists often treat.
- The exact molecular mechanisms behind these side-effects are not fully understood but provide insights into immune tolerance and skin's antitumor immune response.
- A recent study highlights the importance of the PD-1 checkpoint receptor in regulating self-reactive T cells, shedding light on the origin of some of these skin-related reactions.
Article Abstract
Cutaneous side-effects associated with immune checkpoint blockade occur in more than half of patients treated with CTLA-4 and PD-1 inhibitors, and are frequently encountered by dermatologists. The molecular mechanism of cutaneous side-effects is incompletely understood but holds important clues about immune tolerance and the antitumor immune response in the skin. A new landmark study published in suggests a critical functional role for the checkpoint receptor PD-1 in restraining self-reactive T cells, which could help explain how some checkpoint-associated cutaneous side-effects arise.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503525 | PMC |
| http://dx.doi.org/10.1093/bjd/ljad236 | DOI Listing |
Publication Analysis
Top Keywords
cutaneous side-effects
12
insights programmed
4
programmed cell
4
cell death
4
death protein
4
protein blockade-associated
4
cutaneous
4
blockade-associated cutaneous
4
cutaneous immune-related
4
immune-related adverse
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!